Table 2.
Overlapping analysis for DDI studies
| Venn Diagram Area | No. of DDIs in LS result | No. of DDIs predicted by DGI (%) | No. of DDIs found in DrugBank (%) | Top 20 DDIs (Found in DrugBank/ Validated DDIs) |
|---|---|---|---|---|
| Full in-vitro PK area | 3,894 | 3,443 (88.4) | 2,594 (66.6) | 9/17 |
| Full clinical PK area | 3,920 | 2,980 (76.0) | 2,734 (69.8) | 16/20 |
| Full clinical PD area | 17,315 | 8,991 (51.9) | 8,296 (47.9) | 13/19 |
| Overlap of clinical PD – clinical PK – in-vitro PK | 986 | 935 (94.8) | 867 (87.9) | 19/20 |
| Overlap of clinical PK – in-vitro PK | 145 | 139 (95.9) | 112 (77.2) | 19/20 |
| Overlap of clinical PD – in-vitro PK | 1,160 | 1,004 (86.6) | 785 (67.7) | 19/20 |
| Overlap of clinical PD – clinical PK | 2,157 | 1,494 (69.3) | 1,406 (65.2) | 13/19 |
| Only clinical PK | 632 | 412 (65.2) | 349 (55.2) | 13/14 |
| Only in-vitro PK | 1,603 | 1,365 (85.2) | 830 (51.8) | 11/11 |
| Only clinical PD | 13,012 | 5,558 (42.7) | 5,238 (40.3) | 8/18 |
| Venn Diagram Area | No. of DDIs in Venn Diagram Area | No. of DDIs found in DrugBank (%) | Type of Evidence | |
| Clinical PD – clinical PK – in-vitro PK | 6,683 | 3,271 (48.9) | PK Evidence | |
| Clinical PD – in-vitro PK | ||||
| Clinical PK | ||||
| Clinical PD – clinical PK – in-vitro PK | 17,315 | 4,016 (23.2) | PD Evidence | |
| Clinical PD – in-vitro PK | ||||
| Clinical PD | ||||
No.: Number, DDI: drug-drug interactions, LS: literature search, DGI: drug-gene interactions, PK: pharmacokinetics, PD: pharmacodynamics